After 25 years of drug development, do we know JAK?

被引：12

作者：

Mortezavi, Mahta ^{[1
]}

Martin, David A. ^{[2
]}

Schulze-Koops, Hendrik ^{[3
]}

机构：

[1] Pfizer Inc, Inflammat & Immunol, New York, NY 10017 USA

[2] Pfizer Inc, Inflammat & Immunol, Cambridge, MA USA

[3] Univ Munich, Dept Internal Med 4, Div Rheumatol & Clin Immunol, Munich, Germany

来源：

RMD OPEN | 2022年 / 8卷 / 02期

关键词：

Arthritis; Rheumatoid; Pharmacokinetics; Therapeutics; Antirheumatic Agents; RHEUMATOID-ARTHRITIS; TOFACITINIB; CP-690,550; DISCOVERY; MUTATION;

D O I：

10.1136/rmdopen-2022-002409

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 41 条

[1]

[Anonymous], 2017, prescribing information

[2] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[3] A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis [J].

Bechman, Katie ;

Subesinghe, Sujith ;

Norton, Sam ;

Atzeni, Fabiola ;

Galli, Massimo ;

Cope, Andrew P. ;

Winthrop, Kevin L. ;

Galloway, James B. .

RHEUMATOLOGY, 2019, 58 (10) :1755-1766

[4] Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates [J].

Borie, DC ;

Larson, MJ ;

Flores, MG ;

Campbell, A ;

Rousvoal, G ;

Zhang, S ;

Higgins, JP ;

Ball, DJ ;

Kudlacz, EM ;

Brissette, WH ;

Elliott, EA ;

Reitz, BA ;

Changelian, PS .

TRANSPLANTATION, 2005, 80 (12) :1756-1764

[5] Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study [J].

Cervantes, Francisco ;

Ross, David M. ;

Radinoff, Atanas ;

Palandri, Francesca ;

Myasnikov, Alexandr ;

Vannucchi, Alessandro M. ;

Zachee, Pierre ;

Gisslinger, Heinz ;

Komatsu, Norio ;

Foltz, Lynda ;

Mannelli, Francesco ;

Passamonti, Francesco ;

Gilotti, Geralyn ;

Sadek, Islam ;

Tiwari, Ranjan ;

Zor, Evren ;

Al-Ali, Haifa Kathrin .

LEUKEMIA, 2021, 35 (12) :3455-3465

[6] Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases [J].

Clark, James D. ;

Flanagan, Mark E. ;

Telliez, Jean-Baptiste .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (12) :5023-5038

[7] Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition [J].

Dowty, Martin E. ;

Lin, Tsung H. ;

Jesson, Michael I. ;

Hegen, Martin ;

Martin, David A. ;

Katkade, Vaibhav ;

Menon, Sujatha ;

Telliez, Jean-Baptiste .

PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (06)

[8]

European Medicines Agency, 2022, RINVOQ UP SUMM PROD

[9]

European Medicines Agency, Olumiant (baricitinib). Summary of product characteristics

[10]

European Medicines Agency, 2020, JYSELECA FILG SUMM P

← 1 2 3 4 5 →